Dermata Therapeutics Reports $1.8 Million Net Loss in Q1 2026, Shifts Focus to DTC Skincare

Dermata Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $1.8 million, a decrease from a net loss of $2.3 million in the same period of 2025. The company’s total operating expenses for the quarter were approximately $1.9 million, down from $2.3 million year-over-year. This reduction was primarily driven by a significant decrease in research and development expenses, which fell to $383,724 from $1.3 million, attributed to the completion of the XYNGARI™ STAR-1 clinical trial and a strategic shift towards direct-to-consumer (DTC) skincare products. Selling, general, and administrative expenses increased to $1.5 million, reflecting higher marketing and legal costs as the company prepares for its product launch.

As of March 31, 2026, Dermata's cash and cash equivalents totaled $6.9 million, a decrease from $7.5 million at the end of 2025. The company’s total assets also declined to $7.5 million from $7.9 million, while total liabilities decreased significantly from $1.6 million to $1.1 million. The reduction in liabilities was primarily due to lower accrued expenses and accounts payable. Dermata's accumulated deficit increased to $75.1 million, highlighting the ongoing financial challenges as the company transitions to a new business model focused on skincare products.

In terms of strategic developments, Dermata has made a notable pivot from prescription products to DTC skincare solutions, with plans to launch its first product, the Foundational Treatment, in mid-2026. This shift is expected to reduce regulatory burdens and development costs while addressing a broader consumer market. The company has secured inventory of Spongilla raw material, essential for its skincare line, and is evaluating additional procurement opportunities to support future demand.

Operationally, Dermata has seen a significant increase in its employee headcount, reflecting its commitment to expanding its marketing and product development teams. The company has also engaged Wilder & Partners, LLC for branding and marketing services, incurring approximately $0.2 million in related expenses during the quarter. The company’s strategic focus on DTC sales is anticipated to enhance its market presence and consumer engagement, although it remains uncertain when Dermata will achieve profitability.

Looking ahead, Dermata anticipates continued net losses as it ramps up marketing efforts for its upcoming product launch. The company has indicated that it may need to raise additional capital to sustain operations and support its growth strategy. While Dermata's existing cash resources are expected to fund operations into the first quarter of 2027, the company acknowledges the need for further financing to ensure the successful commercialization of its skincare products and to explore potential acquisitions or in-licensing opportunities.